The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy

被引:18
作者
Dunst, J [1 ]
机构
[1] Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle, Germany
关键词
D O I
10.1053/sonc.2001.25395
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute or chronic anemia, a common complication in cancer patients, is associated with the development of tumor hypoxia. It has been shown in several trials that decreased hemoglobin (Hb) levels inducing tumor hypoxia adversely impact radiotherapy or combined radiochemotherapy outcome. For example, pre- and posttreatment Hb levels can be predicitive factors for the outcome of radiotherapy, locoregional tumor control, and survival. Two strategies have been established to correct cancer-related anemia and improve radiotherapy outcome: immediate increase of Hb levels with transfusions, or treatment with recombinant human erythropoietin (r-HuEPO, epoetin alfa), which slowly but steadily increases Hb levels to within normal range. As transfusions are associated with severe risks and adverse events, the use of epoetin alfa to treat preexisting anemia or prevent therapy-induced anemia represents an attractive strategy. The ability of epoetin alfa to maintain or to increase Hb levels in patients undergoing radiotherapy or radiochemotherapy have been shown in several studies in different tumor types. In addition to improving the results of radiotherapy and radiochemotherapy, anemia intervention with epoetin alfa may impact overall survival. Copyright © 2001 by W.B. Saunders Company.
引用
收藏
页码:42 / 48
页数:7
相关论文
共 26 条
  • [1] ANTONADOU D, 1998, RADIOTHER ONCOL, V48, pS122
  • [2] Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
    Becker, A
    Stadler, P
    Lavey, RS
    Hänsgen, G
    Kuhnt, T
    Lautenschläger, C
    Feldmann, HJ
    Molls, M
    Dunst, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02): : 459 - 466
  • [3] Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
    Dubray, B
    Mosseri, V
    Brunin, F
    Jaulerry, C
    Poncet, P
    Rodriguez, J
    Brugere, J
    Point, D
    Giraud, P
    Cosset, JM
    [J]. RADIOLOGY, 1996, 201 (02) : 553 - 558
  • [4] ERYTHROPOIETIN INCREASES HEMOGLOBIN DURING RADIATION-THERAPY FOR CERVICAL-CANCER
    DUSENBERY, KE
    MCGUIRE, WA
    HOLT, PJ
    CARSON, LF
    FOWLER, JM
    TWIGGS, LB
    POTISH, RA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (05): : 1079 - 1084
  • [5] PRETREATMENT HEMOGLOBIN LEVEL INFLUENCES LOCAL-CONTROL AND SURVIVAL OF T1-T2 SQUAMOUS-CELL CARCINOMAS OF THE GLOTTIC LARYNX
    FEIN, DA
    LEE, WR
    HANLON, AL
    RIDGE, JA
    LANGER, CJ
    CURRAN, WJ
    COIA, LR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 2077 - 2083
  • [6] Frommhold H, 1998, STRAHLENTHER ONKOL, V174, P31
  • [7] PROGNOSTIC VALUE OF HEMOGLOBIN CONCENTRATIONS AND BLOOD-TRANSFUSIONS IN ADVANCED-CARCINOMA OF THE CERVIX TREATED BY RADIATION-THERAPY - RESULTS OF A RETROSPECTIVE STUDY OF 386 PATIENTS
    GIRINSKI, T
    PEJOVICLENFANT, MH
    BOURHIS, J
    CAMPANA, F
    COSSET, JM
    PETIT, C
    MALAISE, EP
    HAIE, C
    GERBAULET, A
    CHASSAGNE, D
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (01): : 37 - 42
  • [8] GLASER C, 1998, P AN M AM SOC CLIN, V17, pA397
  • [9] GLASER C, 1999, P ASCO, V18, P1543
  • [10] Grau C, 1998, MED RAD DIA IMG, P101